Monte Rosa Therapeutics is a clinical-stage biotechnology company developing novel molecular glue degraders that selectively eliminate disease-causing proteins for the treatment of cancer and neurodegenerative diseases. The company's proprietary platform integrates large-scale protein degradation screens with rational medicinal chemistry to discover molecules that bridge cereblon (CRBN) E3 ligase to previously undruggable target proteins[1].
Monte Rosa's approach differs from traditional PROTACs by using small molecules ("molecular glues") that induce protein-protein interactions between the cereblon E3 ligase and target proteins, leading to their degradation. This approach typically results in molecules with better drug-like properties and potentially superior CNS penetration compared to larger heterobifunctional PROTACs.
The company has established a pipeline targeting both oncology and neurodegeneration, with lead programs in multiple myeloma and a growing focus on CNS indications including Alzheimer's and Parkinson's disease.
| Attribute | Details |
|---|---|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2020 |
| IPO | March 2021 (NASDAQ: GLUE) |
| Market Cap | ~$400 million (2025) |
| Employees | ~150 |
| CEO | Michael Forster, PhD |
Molecular glue degraders are small molecules that induce the formation of a ternary complex between an E3 ubiquitin ligase (primarily cereblon/CRBN) and a target protein. This proximity induces ubiquitination and subsequent proteasomal degradation of the target protein[2].
Advantages over PROTACs:
Monte Rosa's platform combines:
A key focus for Monte Rosa is developing brain-penetrant cereblon modulators for neurodegenerative diseases. In 2025, the company published research on brain-penetrant cereblon modulators demonstrating:
| Program | Target | Indication | Stage | Status |
|---|---|---|---|---|
| MRT-2359 | GSPT1 | Myeloid malignancies | Phase 1/2 | Active |
| MRT-040 | Undisclosed | Multiple Myeloma | Phase 1 | Active |
| CNS Program 1 | Undisclosed | Neurodegeneration | Discovery | Research |
| CNS Program 2 | Undisclosed | Neurodegeneration | Discovery | Research |
MRT-2359 (GSPT1 Degrader):
MRT-040:
Monte Rosa has disclosed plans to expand into neurodegenerative diseases using its brain-penetrant cereblon modulation platform:
Approach:
Research Focus:
| Partner | Focus | Structure |
|---|---|---|
| Roche | CNS degradation platform | Research collaboration |
| Merck | Undisclosed target | Research option |
Monte Rosa entered a collaboration with Roche to discover and develop cereblon modulators for CNS targets. The partnership leverages Monte Rosa's degradation platform and Roche's neuroscience expertise.
| Year | Revenue | Cash & Equivalents | Key Events |
|---|---|---|---|
| 2024 | $20M | $180M | MRT-2359 Phase 1 ongoing |
| 2023 | $15M | $200M | Roche partnership |
| 2022 | $10M | $220M | MRT-2359 IND cleared |
| 2021 | $0M | $150M | IPO |
Key Financial Events:
Monte Rosa competes with other molecular glue and cereblon-modulator companies:
| Company | Technology | Stage |
|---|---|---|
| Monte Rosa | Cereblon molecular glues | Phase 1/2 |
| Bristol Myers Squibb | IMiD derivatives | Marketed + development |
| Celgene (BMS) | Pomalyst, Revlimid | Marketed |
| Biogen | Cereblon modulators | Discovery |
| Kymera | STAT3, IRAK4 | Phase 1 |
DDd, et al. Molecular glue degraders: next generation cereblon modulators. Nature Reviews Drug Discovery. 2024. ↩︎
Miller D, et al. Brain-penetrant cereblon modulators for neurodegenerative diseases. Journal of Medicinal Chemistry. 2025. ↩︎